Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 689454
                    [Title] => Reducing risk of MS disability progression
                    [Summary] => 
A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 651365
                    [Title] => Data show osteoporosis drug preserves bone mass, provides fracture protection
                    [Summary] => 
Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.
                    [DatePublished] => 2011-01-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. TREVOR MUNDEL

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 689454
                    [Title] => Reducing risk of MS disability progression
                    [Summary] => 
A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 651365
                    [Title] => Data show osteoporosis drug preserves bone mass, provides fracture protection
                    [Summary] => 
Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.
                    [DatePublished] => 2011-01-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Reducing risk of MS disability progression

May 26, 2011 - 12:00am

A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.

Science and Environment

Data show osteoporosis drug preserves bone mass, provides fracture protection

January 27, 2011 - 12:00am

Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.

Science and Environment